Ibyra Olaparib 150mg Tablet

About Ibyra Olaparib 150mg Tablet

Ibyra Olaparib 150 mg Tablet is an oral anti-cancer medication containing Olaparib, a PARP (Poly ADP-ribose polymerase) inhibitor used in the treatment of certain types of cancers. It works by preventing cancer cells from repairing their damaged DNA, leading to cancer cell death while limiting harm to normal cells.

This medicine is primarily prescribed for patients with BRCA-mutated ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer, either as maintenance therapy or in advanced stages, as recommended by an oncologist.

• Composition: Olaparib 150 mg

• Dosage Form: Tablet

• Therapeutic Class: Anti-cancer (PARP inhibitor)

• Route of Administration: Oral

• Prescription Required: Yes

• Ovarian cancer

• Metastatic breast cancer

• Pancreatic cancer

• Prostate cancer (BRCA mutation-positive cases)

Olaparib inhibits PARP enzymes responsible for DNA repair in cancer cells. This leads to accumulation of DNA damage and ultimately results in the death of cancer cells, especially those with BRCA gene mutations.

• To be taken as prescribed by a qualified oncologist

• Tablets should be swallowed whole with water

• Do not crush, chew, or break the tablet

• Nausea and vomiting

• Fatigue

• Anemia

• Loss of appetite

• Diarrhea

• Headache

• Store in a cool and dry place

• Protect from moisture and direct sunlight

• Keep out of reach of children

• Use only under medical supervision

• Not recommended during pregnancy and breastfeeding

• Regular blood tests may be required during treatment